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ANTIGENS AND CANCER PATHWAYS TARGETED BY DE-N-ACETYL 
POLYSIALIC ACID MONOCLONAL ANTIBODIES  
ADARSHA SHIVAKUMAR 
ABSTRACT 
Polysialic acid (PSA) is a developmentally regulated glycan made of repeating 
sialic acid monomers with α2-8 linkages. PSA has very limited expression in adults, and 
modifies only a few cell-surface proteins. However, PSA is overexpressed in several 
human cancers and is associated with metastasis and poor prognosis. We have described 
a derivative of PSA containing a mixture of de-N-acetyl and N-acetyl neuraminic acid 
residues (dPSA) found intracellularly in many normal human tissues but expressed at 
much higher levels on the cell surface of many human cancer cell lines. The proteins 
modified with dPSA and dPSA function in normal and abnormal human biology are 
unknown. The purpose of this study was to identify protein(s) modified with PSA and 
possible dPSA-dependent functions in cancer cell lines that express dPSA antigens. 
Using co-immunoprecipitation with the anti-dPSA monoclonal antibody SEAM 2 and 
mass spectroscopy, we identified membrane-associated nucleolin that is either directly 
modified or associated with dPSA. In addition, knocking down expression of the 
polysialyltransferase ST8SiaII (STX) in SK-MEL-28 human melanoma cells nearly 
eliminated dPSA and nucleolin from membranes but had no effect on the levels of 
nuclear nucleolin, and resulted in aberrant cell morphology, cell adhesion, and motility. 
The data suggest that cell-surface nucleolin depends on modification with dPSA, and that 
dPSA-modified nucleolin has an important role in cell adhesion and migration. 
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INTRODUCTION 
Sialic acids are N- or O-substituted derivatives of the 9-carbon monosaccharide 
neuraminic acid, and are common terminal carbohydrates on eukaryotic cell surface 
glycoproteins and glycolipids. Two common mammalian sialic acids are N-
acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). Polysialic 
acid (PSA) is a glycan made of repeating sialic acid monomers with α2-8 linkages. All N-
linked glycans have a common core pentasaccharide, Man3GlcNAc2, as shown in Figure 
1. Singular sialic acid modifications are common terminal additions to N-linked glycans 
as seen in Figure 2. PSA is made up of 50 to over 370 sialic acid residues (1, 2), making 
them one of the larger glycans added to proteins. Despite its size, PSA is synthesized by 
just two polysialyltransferases that act on N-linked and O-linked glycans (3, 4). These 
polysialyltransferases, ST8SiaIV (PST) and ST8SiaII (STX), are expressed in different 
tissues and amounts postnatally, but have been shown to work cooperatively to 
polysialate proteins (5). Normally, localization of where glycan synthesis occurs is 
difficult because several enzymes are required for their biosynthesis. However, 
identifying the sites of PSA synthesis is less complex since it involves only two specific 
polysialyltransferases. Polysialylation was found to be typically added to N-glycans on 
proteins in the trans most cisternae of the rough endoplasmic reticulum and the trans 
Golgi network (6). 
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Figure 1: Core structure for all N-linked glycans, a common core pentasaccharide, 
Man3GlcNAc2 (7).  
 
 
 
Figure 2: Structure of a complex glycan that contains terminal sialic acid residues, a 
bisecting GlcNAc on the pentasaccharide core, and fucosylation on the core GlcNAc (7). 
 
Polysialylation appears not just to occur in normal human cells, but also in certain 
human tumors: Increased PSA expression has been observed in astrocytoma (8), small 
cell and non-small cell lung carcinoma (9), neuroblastoma (10), and rhabdomyosarcomas 
(11). The antibodies used to detect the PSA expression in these cell lines were all created 
through different means and thus likely have differing epitopes.  
Most glycosyltransferases can modify a huge number of proteins, while 
polysialyltransferases appear to be modify a select few proteins including 
autopolysialylation of the ST8SiaIV and ST8SiaII enzymes (12), synaptic cell adhesion 
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molecule 1 (13), the alpha subunit of the voltage sensitive sodium channel (14), the 
integrin alpha 5 subunit (15), the scavenger receptor CD36 (16), fetuin (17), and 
neuropilin-2 (18). However, the structural features that determine whether and where a 
particular protein is polysialylated are not yet clear. 
The most studied polysialylated protein is the neural cell adhesion molecule 
(NCAM) (19), which is prominent in the developing nervous system. NCAM has six N-
glycosylation sites, but Foley et al. discovered that polysialylation occurs on two N-
glycans located on the fifth immunoglobulin domain (Ig5) of NCAM (20), as shown in 
Figure 3. They also demonstrated a degree of flexibility in polysialylation sites through 
forcing limited polysialylation at some of the other N-glycosylation sites. 
 
 
Figure 3: A schematic representation of the structure of polysialylated NCAM. There are 
six N-glycosylation sites indicated by the black arrowheads. Of those, only the two on the 
Ig5 domain can be polysialylated, and an example of a potential polysialylation is shown 
on the right (21). 
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While the actual impact of polysialylation on protein function at large is still 
being studied, the role of polysialylation in NCAM function has been closely investigated 
(22). When two cell membranes expressed polysialylated-NCAM, the distance between 
them increased, leading Yang et al. to postulate that the steric hindrance of PSA weakens 
contacts between neighboring cells (23, 24). However, the effect of PSA on NCAM is not 
solely inhibitory, as PSA promotes the binding of NCAM to heparan sulfate 
proteoglycans (25, 26, 27). Overall, the impact of PSA on protein binding ability is 
variable, and needs to be examined on a case-by-case basis. 
Our laboratory discovered a novel derivative of PSA, which contains a mixture of 
de-N-acetyl and N-acetyl neuraminic acid residues (dPSA) using monoclonal antibodies 
(mAbs) SEAM 2 and SEAM 3 (28). The mAbs were produced by immunizing mice with 
a PSA derivative-protein conjugate vaccine where the PSA derivative contained about 
16% de-N-acetyl and 84% N-propionyl neuraminic acid residues to enhance 
immunogenicity (28, 29). By using the murine anti-dPSA mAb SEAM 3 to detect dPSA 
expression via immunohistochemistry, dPSA was found to be present in the cells of many 
human tissues (30). However, dPSA is expressed at much higher levels in many human 
cancers compared to cells in the corresponding normal tissues (31). Given the limited 
expression of PSA in normal adult humans, this result was intriguing. The presence of 
dPSA antigens was correlated with increased mRNA expression of the 
polysialyltransferases PST and STX, therefore this could be the mechanism underlying 
the increase in dPSA observed in these cancer tissues (30). Further, we showed that dPSA 
is derived from PSA produced by STX by knocking down expression of that specific 
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polylsialyltransferase (31). While polysaccharide deacetylases are a large family of 
enzymes (32) widely distributed across many species and known to have an important 
role in organismal development, the proteins modified with dPSA, the cell types 
producing dPSA-modified proteins, and the function of dPSA in normal and abnormal 
human biology are unknown. The purpose of this study was to identify protein(s) 
modified with PSA and their possible dPSA-dependent functions. This was accomplished 
by suppressing PSA expression with RNA interference (RNAi) and/or blocking dPSA 
with anti-dPSA monoclonal antibodies in dPSA-expressing cancer cell lines. 
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METHODS  
 
Materials 
 
Cell culture medium along with all supplements were purchased from UCSF Tissue 
Culture Facility (San Francisco, CA) except fetal bovine serum (Gemini Bioproducts, 
West Sacramento, CA). C23 (MS-3) monoclonal mouse antibody was acquired from 
Santa Cruz Biotechnology, CA. SEAM 2 monoclonal antibody was generated in 
Children’s Hospital Oakland Research Institute, as detailed/described below. 14C7, a 
murine IgG3 mAb specific for Neisseria surface protein A, which is an irrelevant antigen 
in human cells, was produced by Dr. Gregory Moe in Children’s Hospital Oakland 
Research Institute (33). All anti-mouse secondary antibodies conjugated with Alexa Fluor 
fluorochromes were obtained from Invitrogen. 
 
mAb SEAM 2 generation and specificity 
 
We used the monoclonal antibody SEAM 2, which along with SEAM 3, was produced by 
immunizing a CD1 mouse with an N-Pr MBPS tetanus toxoid conjugate vaccine (29). 
The specificity and functional activity of SEAM 2 and SEAM 3 have been studied 
extensively (31, 34–36). In a previous study, we showed that the anti-NPr MBPS mAb 
SEAM 3 recognizes de-N-acetyl PSA-containing derivatives (34). SEAM 2 is known to 
recognize a relatively long chain PSA epitope containing more than 10 residues where 
∼50% of the residues are neuraminic acid (35). Of note, SEAM 2 is not reactive with 
PSA-NCAM, even though NCAM is known to have two PSA modifications. This 
discrepancy can be explained by the fact that SEAM 2 recognizes de-N-acetyl PSA-
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containing derivatives, which are different epitopes than the ones recognized by the 
antibodies that have been previously targeting PSA. SEAM 2 used in this study was 
purified by Protein A affinity chromatography from ammonium sulfate precipitated cell 
culture medium provided by QED, Inc. (San Diego, CA). Sodium sulfate was added to 
the solution to a final concentration of 0.5 M and incubated at ambient temperature 
overnight. This step is required to dissociate dPSA antigens that become associated with 
SEAM 2 during cell culture. This solution was then loaded onto a 5 ml HiTrap Fast Flow 
Protein A column (GE Healthcare Bioscience) in buffer (20mM histidine, 0.02% tween 
20, pH = 6.5 adjusted with NaOH). SEAM 2 was then eluted from the Protein A column 
with elution buffer (0.1 M histidine, 0.02% tween 20, pH = 2.7 adjusted with acetic acid 
and HCl). Fractions containing the mAb were immediately neutralized by adding 1M 
NaHCO3 to adjust the pH to ~7.5. The fractions were combined, dialyzed (Spectra Pore, 
10kDa, ThermoFisher) in 0.1M NaHCO3, pH 8, and concentrated (Centraprep Ultracel-
30, EMD Millipore) to ~2 mg/ml as determined by absorbance at 280nm (Nanodrop, 
ThermoFisher). 
 
Cell Culture 
 
SK-MEL-28 human melanoma cells were purchased from ATCC (HTB-72). Cells were 
grown routinely in T75 flasks containing RPMI 1640 medium containing 0.1 mM non-
essential amino acids, 1.0 mM sodium pyruvate, 2 mM glutamine, 
penicillin/streptomycin and 10% fetal bovine serum (FBS) at 37°C in 5% CO2. Confluent 
cells were sub-cultured (1∶3 to 1∶8) by treating with 0.25% (w/v) Trypsin/0.53 mM 
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EDTA solution, and washing in media before re-seeding into new growth medium. SK-
MEL-28 cells were only used up to passage 10 from the original ATCC stock of cells. 
Jurkat cell clone E6-1, a human acute lymphoblastic leukemia T cell line was purchased 
from ATCC (TIB-152). Jurkat cells were grown in T75 flasks containing the same media 
as SK-MEL-28 cells in 5% CO2 at 37°C and subcultured every 3 days with a split ratio of 
about 1∶5. Kelly human neuroblastoma cells were a gift from Dr. Julie Saba, CHORI. 
Kelly cells were grown in T75 flasks containing the same media as SK-MEL-28 cells in 
5% CO2 at 37°C and subcultured every 3 days with a split ratio of about 1∶5. 
Polysialyltransferase knock-down cell lines in SK-MEL-28 human melanoma cells were 
produced by Joshua Lee, Lindsay Stierer and Gregory Moe by vector-based interfering 
RNA (37). The PST1C3 cell line was an STX polysialyltransferase knockdown that did 
not affect expression of PST, while another cell line which had a non-functional 
scrambled RNA plasmid was a negative control. Both cell lines were grown in the same 
media as SK-MEL-28 and Kelly cells in 5% CO2 at 37°C and subcultured every 3 days 
with a split ratio of about 1∶5. Blasticidin was added to the media and cells in T75 flasks 
at a concentration of 10μg/mL to select the plasmid-containing cells. 
 
Protein Extraction from Cells 
 
Approximately 1x105 cells from each cell culture were extracted using the 
ProteoExtract® Subcellular Proteome Extraction Kit (EMD Millipore). In brief, the 
extraction procedure uses four extraction buffers sequentially, along a protease inhibitor 
cocktail to prevent protein degradation during the extraction and Benzonase nuclease to 
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degrade contaminating nucleic acids. The first extraction buffer yields cytosolic proteins, 
the second extraction buffer yields membrane proteins, the third extraction buffer yields 
nuclear proteins, and the fourth and final extraction buffer yields cytoskeletal 
components. The listed instructions for extraction were followed (38), and the cell 
extracts were separated into four fractions: F1 corresponding to the cytosolic fraction, F2 
corresponding to the cell membrane fraction, F3 corresponding to the nucleic protein 
fraction, and F4 corresponding to the cytoskeletal fraction. 
 
Immunodot Blotting 
 
A hybridized nitrocellulose membrane (Immobilon-NC, EMD Millipore) was cut to fit 
the dot blot apparatus (Topac Inc. Instrumentation). The membrane was then pre-wetted 
in PBS buffer for 2 minutes. The membrane was not allowed to dry out before it was 
mounted in the apparatus. 2  of each extracted fraction was then spotted on the top row 
of the membrane. Twofold serial dilutions were done for each fraction down each 
column, up to a 1:16 dilution for each fraction in the appropriate extraction buffer. The 
membrane was then dried for 30 minutes using a vacuum attached to the dot blot 
apparatus. After the fraction samples were spotted onto the membrane, the membrane 
was incubated in a 5% milk solution at 4°C overnight. The membranes were then rinsed 
with PBS three times for five minutes, and then incubated for ninety minutes at room 
temperature with either a 1:200 solution of SEAM 2 in PBS/milk or a 1:200 solution of 
the negative control antibody 14C7 in PBS/milk. The membranes were rinsed again with 
PBS three times for five minutes. Next, the membranes were incubated for ninety 
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minutes at room temperature in a 1:5000 solution of the appropriate IgG secondary 
antibody in PBS/milk. The membranes were rinsed again with PBS three times for five 
minutes and then placed on a Li-Cor Odyssey Infrared Scanner for imaging at 800 
nanometers. 
 
Co-immunoprecipitation 
 
As F1, F2, and F3 were the only fractions to react in the immuno-dot blot, they were the 
only fractions that were further purified through co-immunoprecipitation. Each fraction 
was incubated with Dynabeads M-270 epoxy magnetic beads (Thermofisher) covalently 
linked to SEAM 2 or the irrelevant murine IgG3 mAb 14C7. The beads were separated 
on the side of the tube using a magnet, washed with the respective extraction buffer 
alone, then buffer containing PSA (50 µg/ml) to remove nonspecific binding antigens. 
Finally, buffer containing N-propionyl polysialic acid with 36% de-N-acetyl polysialic 
acid (50 µg/ml, provided by Dr. Gregory Moe) was used to elute the specific binding 
antigens from each fraction. 
 
SDS-PAGE and Coomassie staining 
 
The eluted proteins from each cell fraction were resolved on 4%-12% gradient SDS-
PAGE gels, (NuPAGE, Invitrogen) after adding Sample Buffer (Invitrogen) containing 
reducing agent and heated to 70°C for 10 minutes before loading on the gel. The gel was 
run for 35 minutes at 200V, and then stained with Simply Blue Coomassie stain 
(Invitrogen). 
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LC/MS/MS protein identification 
 
The excised gel slices were extracted overnight in AmBic (50 mM ammonium 
bicarbonate) containing 50% acetonitrile. The disulfide bonds were reduced and modified 
with iodoacetic acid per UCSF In-Gel Digestion Protocol (39) prior to trypsin digest 
(Promega). LC/MS/MS protein identification of tryptic peptides was performed by the 
UC Davis Proteomics Core facility. 
 
Laser scanning confocal microscopy 
 
SK-MEL-28, PST1C3, and scrambled RNA negative control cells (∼105 cell/ml) were 
cultured on multi-well glass coverslips that had been coated with 1:10 human placental 
Type IV collagen (Sigma Aldrich) in 30% ethanol. After an overnight incubation, cells 
were gently washed with PBS and fixed with 4 % formaldehyde in PBS. After one hour, 
the cells were washed with PBS, and half the coverslips had 0.5 ml of ice-cold 0.25% 
Triton X-100 added. The plates were incubated on ice for 10 minute. The Triton and the 
paraformaldehyde were removed and the plates were then blocked in blocking buffer 
(0.5ml solution of 2 % goat serum in PBS/0.25 %Tween) for 1 hour. Next, 200µl of each 
of the following combinations of primary antibodies was added to the pairs (triton treated 
and not treated) of wells:1) negative control 14C7 and 2) SEAM 2 and C23, for one hour 
at room temperature. The C23 was in 1:50 in goat serum/DPBS buffer, while the other 
primaries were all 1:100 in goat serum/DPBS buffer. The cells were then gently washed 
with sterile PBS before goat anti-mouse isotype-specific secondary antibodies conjugated 
to Alexa Fluor 488 or Alexa Fluor 594 (ThermoFisher) were added (1:200 dilution) in 
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blocking buffer to each well for at least one hour at room temperature in the dark. 
Subsequently, the cells were washed with PBS/Tween, then PBS. Finally, 200µl of .5% 
DAPI in PBS was added to each well for ten minutes. The cells were then washed with 
PBS one more time, and then mounted using a hardening mounting medium (Electron 
Microscopy Sciences) and left to dry overnight. Confocal images were obtained using a 
Zeiss LSM710 laser scanning confocal microscope (CHORI) and analyzed using ImageJ 
Software (40) and JACoP (41). 
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RESULTS 
We had established in previous studies that human melanoma SK-MEL-28 cells 
are relatively high expressers of dPSA antigens that are reactive with anti-dPSA mAbs 
SEAM 2 and SEAM 3 (31, 37). SEAM 2 recognizes a dPSA epitope containing at least 
10 residues, 30%-50% of which 
are de-N-acetyl polysialic acid 
(Figure 4). Furthermore, SK-
MEL-28 cells are adherent with a 
relatively large cytoplasm 
making them advantageous with 
respect to identifying dPSA 
antigens in subcellular structures. 
 
SK-MEL-28 cells were 
processed by differential 
detergent solubility into fractions 
enriched in cytosolic, membrane, 
nuclear, and cytoskeletal proteins 
(fractions F1, F2, F3, F4, 
respectively). The presence of 
dPSA antigens in each fraction 
was determined by immunodot 
blot with detection using anti-
 
Figure 4: The SEAM 2 and SEAM 3 mAbs both 
bind to the de-N-acetyl PSA containing 
derivatives, but SEAM 2 binds to derivatives with 
a longer epitope, as shown in the figure. 
 
Figure 5: Immunodot blot of SK-MEL-28 cell 
fractions. SEAM 2 marks dPSA antigens mainly in 
Fraction 2 and to a lesser extent in Fraction 3. 
Very minor staining of F1 and no staining of 
Fraction 4 were observed. There was no staining 
with an irrelevant IgG3 mAb on the left. 
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dPSA mAb SEAM 2. The membrane fraction (F2) was the most reactive with SEAM 2 
(Figure 5).  
To identify molecules modified with SEAM 2-reactive dPSA antigens, fractions 
F1-F3 were combined with SEAM 2 or an irrelevant murine IgG3 mAb (14C7) 
covalently linked to magnetic beads. Fraction 4 was not subjected to co-
immunoprecipitation since this 
fraction was not reactive with 
SEAM 2 in the immunodot 
blot and contains sodium 
dodecyl sulfate, which 
inactivated SEAM 2 binding 
activity. The beads were 
washed with PSA in the 
respective extraction buffer to 
remove antigens binding non-specifically. SEAM 2-specific binding antigens were then 
eluted with N-propionyl polysialic acid containing 36% de-N-acetyl polysialic acid. 
SEAM 2 has about 200 times greater avidity for this antigen than dPSA containing N-
acetyl neuraminic acid residues (G. Moe, unpublished). The eluted proteins were resolved 
on SDS-PAGE gels. As shown in Figure Z, only the sample from the SEAM 2-F2 co-
immuno-precipitation contained proteins staining with Coomassie, which appear largely 
as a “smear” rather than distinct bands. Typically, proteins modified with PSA run in 
SDS-PAGE gels over a relatively wide range of apparent mass because of the 
 
Figure 6: SDS-PAGE gel of immuno-co-
precipitated fractions from SK-MEL-28 cells. The 
gel was stained with Coomassie and gel slices 
indicated by the black arrows labeled P1-P4 were 
excised and processed for LC/MS/MS analysis of 
tryptic peptides. 
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heterogeneity of polysialylation. Variable amounts of PSA de-N-acetylation likely 
produces additional heterogeneity. Four relatively dark staining regions of the gel were 
excised from the gel and processed to generate tryptic peptides for LC/MS/MS mass 
fingerprinting (labeled P1-P4 in Figure 6). As controls, gel slices were taken from the 
same relative positions in the sample from the F2-irrelevant IgG3 mAb co-
immunoprecipitation.  
 
Identification of SEAM 2 antigen 
 
The tryptic peptide LC/MS/MS analysis of the bands (figure not shown) excised 
from the SEAM2-F2 immuno-precipitate identified nucleolin (14 exclusive peptides, 16 
unique spectra, 167/710 amino acids identified ranging from residues 139-624) as the 
predominant protein in slices marked P1(~145 kDa) and P2 (~115 kDa).  In addition, 
there were trace amounts of several ribosome-associated proteins in both fractions. Slices 
marked P3 (~71 kDa) contained ribosome-associated proteins and alpha-tubulin and P4 
(~48 kDa) contained ribosome-associated proteins and actin. There were no proteins 
identified in the control slices. The calculated molecular mass of nucleolin is 77 kDa, but 
due to multiple covalent modifications, the presence of highly acidic regions near the N-
terminal region, and self-cleaving activity nucleolin can have several apparent masses 
ranging from ~100 kDa to ~50 kDa (42, 43). The experiment was repeated and included 
an additional control of co-immunoprecipitation with the anti-PSA mAb SEAM 12 (data 
not shown). Again, nucleolin was the predominant protein in gel slices corresponding to 
P1 and P2 (39% sequence coverage), with smaller amounts of nucleolin also present in 
the SEAM 12 co-immunoprecipitate and much less in the irrelevant control. 
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The same co-immunoprecipitation procedure of subcellular enriched cell fractions 
was repeated for Kelly neuroblastoma and Jurkat T lymphocyte cells. SEAM 2 was found 
to co-immuno-precipitate nucleolin from F2 of Kelly cells (19 exclusive unique peptides, 
22 exclusive unique spectra, 190/710 amino acids) and F1 in Jurkat cells (15 exclusive 
unique peptides, 25 exclusive unique spectra, 308/710 amino acids) that was not present 
in corresponding gel slices of the irrelevant negative control mAb (figure not shown). 
 
Morphological differences between stable, chromosomally expressed RNAi 
knockdown of polysialyltransferase ST8SiaII (STX) and a scrambled negative 
control mutant of SK-MEL-28 cells. 
 
SK-MEL-28 cells express the two polysialyltransferases ST8SiaII (STX) and 
ST8SiaIV (PST). STX is highly expressed during normal fetal development but is 
abnormally overexpressed in many human cancers PST is expressed at low levels in a 
         Scrambled Negative Control                                STX RNAi knockdown 
        
Figure 7: Morphological changes resulting from RNAi knockdown of 
polysialyltransferase ST8SiaII (STX). The negative control “scrambled” SK-MEL-28 
cell line has normal morphology characterized by an extended structure with lamellipodia 
extending from leading and lagging ends of cell movement. The RNAi STX knockdown 
cell line lacks the extended structure and contains large numbers of lamellipodia.  
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variety of human tissues (5). Previously, it had been shown that transient STX siRNA 
knockdown in SK-MEL-28 cells decreased production of PSA and dPSA, demonstrating 
that dPSA is derived from PSA. Subsequently mutant SK-MEL-28 cell lines were 
generated by chromosomal integration of plasmids expressing siRNA targeting PST and 
STX (37). As shown in Figure 7 above, RNAi knockdown of STX alone resulted in an 
altered cell morphology compared to a negative control cell line with a chromosomally 
integrated plasmid expressing a scrambled RNA having wild-type cell morphology. The 
cells with STX RNAi knockdown are characterized as being smaller with a large number 
of lamellipodia arrayed in a circular pattern around a dense cytoplasm centered on the 
nucleus.  
 
dPSA and nucleolin are co-localized in SK-MEL-28 cells and inhibiting production 
of PSA decreases dPSA-nucleolin on the cell surface 
 
Since anti-dPSA mAb SEAM 2 immuno-co-precipitated nucleolin, we asked the 
question of whether nucleolin is co-localized with dPSA in SK-MEL-28 cells. To address 
this question, we used laser scanning confocal fluorescence microscopy with anti-
nucleolin mAb C23 to mark nucleolin and SEAM 2 to mark dPSA. As a control, the cells 
were stained with an irrelevant murine IgG3 mAb and the secondary antibodies. As 
shown in Figure 8 below, there was no staining with the irrelevant mAb or secondary 
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antibodies alone. In wild-type SK-MEL-28 cells, dPSA (red fluorescence) was present on 
the surface of cells and was concentrated in vesicle-like structures at the leading and 
lagging ends of the cell and at points of possible lamellipodia development. Anti-
nucleolin staining (green fluorescence) was identical with respect to location and 
intensity of staining (merge).  Next, we looked at staining patterns inside cells by treating 
fixed cells with the detergent Triton-X100 to permeabilize them and allow entry of 
primary and secondary antibodies. dPSA inside cells exhibited a web-like pattern typical 
of the most trans endoplasmic reticulum (ER) and golgi. Both are known to be sites 
where polysialylation occurs. Also, dPSA staining was concentrated in leading and 
lagging protrusions and in vesicle-like structures of possible lamellipodia development. 
Again, anti-nucleolin staining matched that of anti-dPSA inside cells with respect to 
location and intensity of staining. The exception was the intense anti-nucleolin staining 
around the nuclear membrane, which was completely devoid of anti-dPSA staining. The 
negative control SK-MEL-28 mutant expressing the scrambled RNA was similar to the 
wild-type strain with respect to pattern of staining, co-localization of nucleolin with 
dPSA, and differences in dPSA staining with nuclear membrane nucleolin. Finally, we 
  
Figure 8. Fluorescence micrograph of SK-MEL-
28 cells containing a chromosomally integrated 
plasmid expressing negative control “scrambled” 
RNA stained with an irrelevant murine IgG3 mAb 
and goat anti-mouse IgG2a conjugated Alexa Fluor 
488 (green fluorescence) and goat anti-mouse 
IgG3 conjugated Alexa Fluor 594 (red 
fluorescence) secondary antibodies. Nuclear DNA 
was stained with DAPI (blue fluorescence). 
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looked at the effect of reduced production of dPSA in the STX RNAi knockdown cell 
line. As shown in Figure 9, the STX knockdown has the characteristic circular 
morphology with multiple lamellipodia shown in Figure 7, above. Cell surface dPSA and 
nucleolin were greatly diminished in the STX RNAi mutant. Similarly, the cytoplasmic 
distribution of dPSA and nucleolin were reduced but STX knockdown had no effect on 
anti-nucleolin staining of the nuclear membrane.  
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Figure 9: Fluorescence micrographs of wild-type SK-MEL-28, negative control mutant 
expressing a scrambled siRNA, and STX knockdown mutants. dPSA is marked with anti-
dPSA mAb SEAM 2 (red fluorescence), nucleolin with anti-nucleolin mAb C23 (green 
fluorescence, and DNA with DAPI (blue fluorescence). Cells were permeabilized as 
indicated to allow detection of intracellular dPSA and nucleolin. The figure shows that 
dPSA is co-localized with nucleolin except for nucleolin in the nuclear membrane, that 
the presence of nucleolin in the cytoplasm and cell surface depends of the production 
dPSA, and that dPSA-nucleolin is concentrated in the cell structures at the leading and 
lagging lamellipodia. 
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DISCUSSION 
Co-immunoprecipitation of the membrane fraction from SK-MEL-28 and Kelly 
neuroblastoma cells with anti-dPSA mAb SEAM 2 identified nucleolin as either directly 
modified or associated with de-N-acetyl polysialic acid (dPSA). Furthermore, laser 
scanning confocal microscopy of SK-MEL-28 cells showed that SEAM 2-reactive dPSA 
was co-localized with cell surface and intracellular membrane-associated nucleolin but 
not nuclear nucleolin. The results suggest that dPSA-modified nucleolin is a distinct form 
of the protein. Nucleolin is an evolutionarily conserved protein, with homologs found in 
yeast (44) and plants (45). The nucleolin gene contains 14 exons with 13 introns and 
spans 11kbp (710 AA, 76,614 Da), and there are no known splice variants. The base 
structure of nucleolin consists of three multifunctional domains: an N-terminal region 
containing several acidic stretches, a central region containing two to four RNA-binding 
domains, and a C-terminal region rich in glycine/arginine. Nucleolin is found throughout 
the cell, and has been detected in the cytoplasm, nucleus, nucleoli, and the cell 
membrane. In non-cancerous cells, nucleolin is predominantly located intracellularly, 
except in the cases of epithelial cells, where it is found outside on the cilia (46). 
Similarly, anti-dPSA reactivity with SEAM 2 is present in cilia but not on the cell surface 
of normal epithelial cells (G. Moe, unpublished). However, in cancer cells, nucleolin has 
been shown to be expressed consistently and abundantly cell surface (47, 48). The reason 
for this difference in nucleolin expression patterns is due to post-translational 
modifications, which modify the functionality and localization of nucleolin. 
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Nucleolin’s post-translational modifications include phosphorylation (49), 
methylation (50), ADP-ribosylation (51), small ubiquitin-like modification (SUMO) (52), 
and glycosylation-including sialylation although polysialylation of nucleolin was not 
known to occur (53). Nucleolin is a highly phosphorylated protein, and the N-terminal 
region is phosphorylated by major protein kinases such as casein kinase 2 (CK2) (49) and 
cyclin-dependent kinase 1 (CDK1) (54). This phosphorylation has been shown to be 
necessary for nucleolin to translocate to the cell surface (55). Nucleolin has 
approximately one-third of the arginine residues being methylated, which impacts its 
ability to interact with DNA and RNA (56). ADP-ribosylation of nucleolin has been 
reported, but the residues targeted and the impact on nucleolin’s functionality is 
unknown. 
Carpentier et al. identified two N-glycosylation sites on the extranuclear nucleolin 
isoform at positions N317 and N492, which are on the edge of the RNA-binding cleft of 
the RNA-binding domains RBD1 and RBD3 (53). They also identified one other 
potential N-glycosylation sites along the RNA-binding domains. N317 is also near a 
highly acidic segment similar to those identified as being essential for 
polysialyltransferase docking (57). Hoja-Lukowicz, Kedracka-Krok, Duda, and Litynska 
showed that cell surface but not cytoplasmic nucleolin was modified with α2-3- and α2-
6-linked sialic acids (58). Although specific structural determinants for polysialylation 
are not known, polysialyltransferases require substrate glycans containing at least one 
sialic acid residue to initiate polymerization (57). SK-MEL-28 cells express both PST 
and STX polysialyltransferases. However, knocking down expression of just STX 
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resulted in almost complete loss of SEAM 2 reactivity and membrane-associated 
nucleolin, which is consistent with cell surface/membrane-associated nucleolin being 
directly modified with dPSA derived from STX polysialylation. STX expression in 
normal adult cells is almost completely suppressed (5). In contrast, STX expression is 
high during fetal development and in many human cancers such as small cell lung cancer, 
neuroblastoma, and adenocarcinomas of the breast, ovary, pancreas, and stomach (59). 
Similarly, these cancers are also high expressors of dPSA, as measured by reactivity with 
anti-dPSA mAbs and cell surface nucleolin (30). Polysialylation of nucleolin may not 
have been recognized previously because lectins and anti-PSA antibodies do react with 
dPSA and neuraminidases that degrade PSA have no effect on depolymerizing dPSA (T. 
Bandarhi and G. Moe, unpublished).   
The function of cell surface nucleolin and dPSA is not known. However, the 
phenotypic effect of knocking down STX expression and the corresponding effect on 
dPSA-modified/associated nucleolin provides some clues. Cell surface dPSA-modified 
nucleolin was concentrated in vesicle-like structures in small protrusions at the leading 
and lagging ends of SK-MEL-28 cells expressing the polysialyltransferase STX but not in 
cells with STX expression knocked down. The latter cells also exhibited an aberrant 
morphology characterized by multiple narrow lamellipodia and a defect in cell motility 
(37). The movement of cells on surfaces is a complex process involving more than 300 
proteins (60). The extension of lamellipodia and their adherence to the substrate is a 
critical component of cell motility and metastasis in normal cancer cells. Disrupting 
complexes made of cell surface nucleolin and other surface proteins through 
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pseudopeptide binding has shown a variety of inhibitory effects on various cancer cell 
lines, including inhibition of cell adhesion and migration (61). Nucleolin has also been 
discovered to interact with and affect several cytoskeletal elements. Thus, changes in 
nucleolin structure or expression could plausibly impact cellular motility. Hovanessian et 
al. found that cell surface nucleolin is able to cluster in specific patterns through 
interactions with actin filaments of the cytoskeleton, and that cell surface nucleolin can 
mediate the intracellular import of various ligands (62). Gaume et al. discovered that 
nucleolin expression plays a role in microtubule stabilization. However, they were unable 
to determine if nucleolin directly associated with microtubules or if it indirectly affected 
microtubule stability through interactions with actin or through regulation of microtubule 
associated proteins (63). As actin filaments and microtubules are critical cytoskeletal 
elements of cell movement and lamellipodia formation, the polysialylation of nucleolin 
could affect cellular motility and thus tumor progression and metastasis. The discovery 
that cell surface nucleolin interacts with integrins to enable cell migration in human 
glioblastomas and melanomas supports this idea, as cell surface nucleolin is often 
glycosylated (64, 65). Cell surface nucleolin has also been shown to facilitate and 
stimulate macropinocytosis in cancer cells (66), a specific type of endocytosis dependent 
on the actin skeleton and implicated with cell motility (67). 
Separately, polysialylation, especially by STX, and sialic de-N-acetylation have 
also been shown to affect cell motility. Cytidine monophosphate-N-acetyl neuraminic 
acid (CMP-NANA) is the substrate for polysialyltransferase PSA polymerization. Excess 
CMP inhibits CMP-NANA formation without also being cytotoxic. Al-Saraireh et. al. 
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showed that CMP inhibited cell surface PSA production and significantly reduced the 
ability of several neuroblastoma cell lines to migrate in a CMP concentration-dependent 
manner (68). Further, they showed the effect was specifically the result of inhibiting 
STX. Since the cell lines tested are known to express dPSA antigens (31) and dPSA is 
derived from PSA, it is possible that the effect of inhibiting STX also affected dPSA. In 
addition, Liu et. al. provided direct evidence that sialic de-N-acetylation occurs 
specifically in metastatic melanoma and is important for cell migration and invasion (69). 
They showed de-N-acetyl ganglioside GM3 promoted cell migration and invasion 
through urokinase plasminogen activator receptor signaling that activated matrix 
metallophroteinase-2. Currently, no sialic acid de-N-acetylases have been identified, so it 
is uncertain whether there are specific sialic acid de-N-acetylases for sialylated molecules 
that contain only a couple of residues, such as the gangliosides, and longer polymers such 
as PSA. However, our studies (30, 31, and this study) and previous studies of de-N-acetyl 
gangliosides in melanoma (69, 70) clearly establish that sialic acid de-N-acetylation is 
prevalent in melanoma and has a role in cell migration. 
Nucleolin is also known to be involved in a large variety of intracellular and 
extracellular processes in normal and cancer cells. Intracellularly, it is involved in 
ribosome biogenesis, cytokinesis, nucleogenesis, cell proliferation and growth, chromatin 
remodeling, DNA repair, regulation of mRNA translation, and receptor signaling (71). 
The N-terminal domain of NCL also interacts with histones and DNA. Specifically, the 
phosphorylated N-terminal domain nucleolin has been shown to bind to histone H1 and 
induce chromatin decondensation (72). The C-terminal domain of nucleolin has been 
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shown to interact with and bring together ribosomal RNA and proteins (73, 74). 
Nucleolin is also shown to be critical for the functionality of RNA Polymerase I (75). 
Nucleolin also binds to or interacts with many proteins that have been shown to play a 
role in tumor proliferation and DNA repair/damage. Wise et al. discovered that nucleolin 
binds to the critical cancer cell survival factor Fas through glycine/arginine rich domains 
in the N-terminal, and that B-cell lymphomas with surface nucleolin-Fas complexes are 
resistant to Fas-mediated apoptosis (76). Farin et al. reported that nucleolin interacts with 
the oncogenic protein Ras in a unique manner. There are many Ras variants, and each can 
exist in a GTP and GDP bound state that have different 3D configurations and thus bind 
to different molecules. However, nucleolin binds to not only all Ras isoforms, but also 
both the GDP and GTP-bound Ras forms (77). Nucleolin also binds to the human 
telomerase reverse transcriptase subunit through its fourth RNA-binding domain and the 
carboxyl-terminal RGG domain in the C-terminal end (78). By doing this, nucleolin 
appears to be involved in assembly or maturation steps of telomerase (79). Other proteins 
known to bind to and be regulated by nucleolin include Fragile X Mental Retardation 
Protein, hepatocyte growth factor, Tumor Necrosis Factor alpha inducing protein, and 
Proliferating Cell Nuclear Antigen (80-83). 
In this study, we have identified cell surface and intracellular membrane-
associated nucleolin as a SEAM 2 antigen likely directly modified with dPSA. We have 
also shown that STX has a critical role in defining SK-MEL-28 cell morphology and 
enabling cell motility. Since cell adhesion and motility are important in cancer cell 
metastasis, particularly in melanoma, and anti-dPSA mAbs could have cytotoxic effects 
   
27 
on SK-MEL-28 cells. Therefore,  this study has the potential to open the way to new 
approaches to preventing and treating cancers that produce cell surface dPSA-modified 
nucleolin. 
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